PNH
Haematology · 2010–2024
2decisions
2medicines
1carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| iptacopan Treatment of adults with paroxysmal nocturnal haemoglobinuria (PNH) who have inadequate clinical response to Complement 5 (C5) inhibitor treatment. | Jul 2024 | Recommended with restriction | input received |
| eculizumab Treatment of paroxysmal nocturnal haemoglobinuria (PNH) to reduce haemolysis. | Jul 2010 | Recommended | no section in document |
What the PBS pays
$37M in government benefit over 2024–25, across 902 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| eculizumab | $37.1M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.